Integral Diagnostics Ltd
ASX:IDX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.1052
3.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
IDX
stock under the Base Case scenario is
4.795
AUD.
Compared to the current market price of 2.465 AUD,
Integral Diagnostics Ltd
is
Undervalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Integral Diagnostics Ltd.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Heightened cost pressures from radiologist staffing shortages and wage inflation could squeeze margins, especially if Integral Diagnostics struggles to recruit and retain top talent across its expanding network.
Regulatory changes or tighter government reimbursement policies in Australia and New Zealand may constrain revenue growth and reduce profitability, given the company’s reliance on public health funding for diagnostic services.
Integration risks from ongoing acquisitions could lead to operational inefficiencies, eroding economies of scale and delaying the anticipated benefits of expansion.
Growing demand for advanced imaging services, underpinned by an aging population and higher chronic disease prevalence, should drive sustained growth for Integral Diagnostics’ broad service offering.
A robust acquisition pipeline and successful integration of newly acquired clinics could strengthen the company’s geographic footprint and enhance bargaining power with payers and suppliers.
Ongoing investment in cutting-edge imaging technology and digital platforms may boost clinical efficiency, attract high-caliber radiologists, and create a competitive edge in specialized diagnostic services.
Revenue & Expenses Breakdown
Integral Diagnostics Ltd
Balance Sheet Decomposition
Integral Diagnostics Ltd
| Current Assets | 95.3m |
| Cash & Short-Term Investments | 52.1m |
| Receivables | 28.5m |
| Other Current Assets | 14.7m |
| Non-Current Assets | 1.3B |
| Long-Term Investments | 5k |
| PP&E | 468.8m |
| Intangibles | 862.4m |
| Current Liabilities | 140.7m |
| Accounts Payable | 64.5m |
| Other Current Liabilities | 76.2m |
| Non-Current Liabilities | 592.8m |
| Long-Term Debt | 564.7m |
| Other Non-Current Liabilities | 28.1m |
Free Cash Flow Analysis
Integral Diagnostics Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Integral Diagnostics Ltd
|
Revenue
|
628m
AUD
|
|
Cost of Revenue
|
-28.1m
AUD
|
|
Gross Profit
|
599.8m
AUD
|
|
Operating Expenses
|
-541.6m
AUD
|
|
Operating Income
|
58.3m
AUD
|
|
Other Expenses
|
-53.6m
AUD
|
|
Net Income
|
4.7m
AUD
|
IDX Profitability Score
Profitability Due Diligence
Integral Diagnostics Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Integral Diagnostics Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
IDX Solvency Score
Solvency Due Diligence
Integral Diagnostics Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Integral Diagnostics Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDX Price Targets Summary
Integral Diagnostics Ltd
According to Wall Street analysts, the average 1-year price target for
IDX
is 3.498 AUD
with a low forecast of 3.232 AUD and a high forecast of 4.2 AUD.
Dividends
Current shareholder yield for
IDX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IDX
stock under the Base Case scenario is
4.795
AUD.
Compared to the current market price of 2.465 AUD,
Integral Diagnostics Ltd
is
Undervalued by 49%.